In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

In December 2023, the US Food and Drug Administration (FDA) approved Casgevy and Lyfgenia, cell-based therapies that modify a person's genes and prevent the "sickling" of red blood cells.

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Casgevy, the first approved CRISPR gene-editing therapy, is picking up momentum in treating sickle cell disease and transfusion-dependent beta-thalassemia. The U.S. Food and Drug Administration ...

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli ...

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...